Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Ireland CDMO Directory · Dundalk, Co. Louth

WuXi Biologics Dundalk

Biologics Drug Substance & Drug Product

600+ (2024 campus figure)
Employees
48,000L Bioreactor Capacity
Facility
Louth
County
2
Certifications

Facility Overview

Ireland's first WuXi Biologics manufacturing site (announced 2018, €325M initial investment), featuring 48,000L fed-batch bioreactor capacity using single-use and continuous bioprocessing technology. Distinct from the adjacent WuXi Vaccines facility on the same campus, which was sold to Merck/MSD in 2025 — this biologics drug substance/drug product plant remains WuXi-operated and gained EMA commercial manufacturing approval in August 2025.

ISPE Facility of the Year 2023 — 48,000L single-use biomanufacturing plant

Capabilities

Biologics Manufacturing Single-Use Bioreactors Monoclonal Antibodies Recombinant Proteins Continuous Bioprocessing

Certifications & Regulatory Licenses

HPRA Licensed EMA (EU GMP) — commercial approval Aug 2025
Sourcing & Facility Audit

Considering WuXi Biologics Dundalk for your shortlist?

Tell us your molecule type, dosage form, batch size, and target markets. We coordinate a direct introduction and independent facility assessment.

Request Sourcing & Audit →